Member Info for cottoner

?

We have received written confirmation of Newsummit Biopharma's intention to pay the amounts owed as part of ongoing discussions to extend its working relationship with the Group.

We are Hiring! Six new vacancies in our labs in #NAFIC, York UK. Closing date is 6th December.

*Histology Scientist
*Production Manager
*Histology Technician
*Services Manager
*Services Scientist
*Tissue Culture Specialist
Each role description includes:

As we are expanding rapidly there is potential for the role to grow with you, as you take on more responsibility. There will also be the opportunity to gain further qualifications within the biosciences field.

With regards to volume of trades , it's always worth bearing in mind that there are only just under 14.5m shares in total.

Since Nov 11th (inc today) there have been over 2.2m shares traded , which is over 15% of the total number of shares.

That's following the 3 very large volume days (Nov 6- 8).

Looks like there are a number of PIs who managed to get some of HC's shares at a very low price and are happy to cash them in with a pretty good profit.

For info:

He actually stepped down on the 7th Nov.

There was a volume of over 8m shares traded on the 7th.

There were over 3.5m shares traded on Nov 6th and over 1.5m shares traded on Nov 8th.

For info/interest

Half-year results were released on Dec 20th last year.

Clue might be in the word 'remaining'

The remaining amount of the Cash Payment (€ 23,046,142) and the Interest Amount, shall be paid to the trustee of the (Series A) convertible bonds of the Company ("Trustee").

A cash payment of €39,554,332 (the "Cash Payment"), plus the Interest Amount[2] that shall be paid on closing date.

Rainmaker shall be entitled to receive a total sum of €19,050,000: (i) a sum of € 16,508,190 out of the Cash Payment

The remaining amount of the Cash Payment (€ 23,046,142) and the Interest Amount, shall be paid to the trustee of the (Series A) convertible bonds of the Company

Any views - can sell (2.72) but no quote online to buy in over an hour.

No , a company doesn't have to but on this occasion NFX did.

It didn't just state that it is talks with several companies , it stated :

It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme.

A few hundred companies on the LSE are not doing the above only NFX.

A few hundred companies on the LSE are I presume involved in several talks as you put it but that doesn't mean that the specific NFX discussions are more or less advantageous.

My last word on this, at the end of the day everyone must decide for themselves whether or not they believe NFX is a good investment for the future or not.

And your point is?

I'm Cottoner by the way not Cotton.

If it was fake news - NFX would have had to say as much in their RNS - they did not.

Major article in todays Sunday Times about Illumina and the future of genetic testing.

A few extracts

“In the future, an individual’s genome is going to be an essential part of their health record,” said deSouza, 48, a former Microsoft executive who has led Illumina since 2016.

It is hard to overstate the potential of genetic technology, both economically and medically. Blurring the lines between computing and medicine, it is the type of technology that swathes of the economy could be built around.

In future, deSouza predicts Illumina’s technology will mean that babies can be tested for rare diseases in the womb through a simple blood test of the mother. Parents of children with rare genetic diseases could cut the wait time for a diagnoses from seven years to days.

These are innovations that will save healthcare systems billions of pounds. In America, almost 10% of families with a child with a rare genetic illness go bankrupt because of the medical costs of waiting for a diagnosis, said deSouza.

Despite Illumina’s size, and market dominance, deSouza said the world was still just at the beginning of the genomics revolution. His optimism is echoed across the UK, where companies are springing up seeking to use, and improve, on Illumina’s work.

https://www.thetimes.co.uk/edition/business/the-ones-that-got-away-ddq32s3rj

IN short , NO - think lowest but was at 56.5p.

Reports Results from Novel IPF Pre-Clinical Trial
RNS Number : 1394J
Nuformix PLC
03 December 2018

NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)

For info:

FDA approved Esbriet for treatment of idiopathic pulmonary fibrosis in 2014. The drug, whose revenue stood at $48 million in 2014, garnered nearly $856 million in 2017

The Times repeated the 'news' in its Market Report this morning.

'Nuformix, a Cambridge-based drug company, shed 1¾p, or 14.8 per cent, to 10p, having confirmed that one of its lenders had converted its loans into shares after the share price jumped by 43 per cent on Friday. That lender was Alan Miller, chief investment officer of SCM Direct, a wealth manager, who is married to Gina Miller, the anti-Brexit campaigner. Last week, the company confirmed that it was in talks with “multiple potential licensees in Japan and Asia”.'

Not actually true , buys at first bell @ 8.3p

annual royalty payments worth more than £200 million sounds pretty good to me!

There was a deal ages ago.

Will it be passed is another issue.
DUP.

See CORO twitter

Asian Endeavour 1 rig is now on location and pre-loading in preparation of spu

It seems to be widely accepted that the NFX chairman has been in China over the past week having discussions with our Chinese partners.
If this is the case then I believe it is incumbent on NFX to release an RNS early next week giving some details of what came out of those meetings and what the latest position is.
A listed company must issue without delay developments which may lead to a substantial price movement or avoid the creation of a false market.
In the recent news vacuum regarding the awaited milestone payments from China, widely ranging views from, NFX won't be paid by their Chinese partners and their patents have been stolen , to their Chinese partners want to extend the partnership and invest in NXP002 have been touted.
The truth probably lies somewhere in between - but no-one (outwith NFX) knows for sure.
After the meetings this week NFX must surely now have enough information to share with the market. They obviously must know why the payments have been delayed and should by now be able to give this reasons and what the outcome will be, likely to be or what the next steps are.
Positive news regarding the milestone payments may likely cause the SP to go substantially higher, negative news may cause the SP to go substantially lower.
I believe there is a holiday in China all next week so further discussions then may be unlikely.
Thus IMO , NFX should release what news they have on the subject now or they risk the creation of a false market.